Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 To 4.0 ng./ml. range

Keyphrases

• Benign Condition 10%
• Benign Disease 10%
• Cancer Disease 10%
• Cancer-free 10%
• Cut-off Low 10%
• Digital Rectal Examination 10%
• Gray Zone 10%
• High Sensitivity 10%
• Negative Biopsy 10%
• Organ-confined 10%
• Pathological Criteria 10%
• Prostate Cancer 10%
• Prostate Cancer Screening 10%
• Prostate-specific Antigen 50%
• Prostatic Biopsy 30%
• Radical Prostatectomy 10%
• Risk Assessment 10%
• Screening Study 10%
• Total Prostate-specific Antigen 100%
• Tumor 30%
• Unnecessary Biopsy 100%

Medicine and Dentistry

• Benign Tumor 6%
• Biopsy Technique 100%
• Cancer 13%
• Cancer Screening 6%
• Digital Rectal Examination 6%
• Malignant Neoplasm 26%
• Neoplasm 20%
• Prostate Biopsy 20%
• Prostate Cancer 13%
• Prostate Specific Antigen 100%
• Prostatectomy 6%
• Volunteer 6%